Roche's Genentech Reports Phase Ib Results For Its Dual GLP-1/GIP Receptor Agonist CT-388 In People With Obesity

Author: Benzinga Newsdesk | May 16, 2024 02:13am

Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) –
At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss –
In a subgroup with pre-diabetes at baseline, CT-388 treatment normalized glycemia in all patients, indicating its strong impact on glucose homeostasis –
No new or unexpected safety signals were detected. Overall, CT-388 demonstrated a safety and tolerability profile consistent with its drug class –

Posted In: RHHBF RHHBY RHHVF